StockData
Teladoc Health, Inc. logo

Teladoc Health, Inc. (TDOC) stock

TDOCNYSEServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/3043% below fair value
$8.49−0.21 (-2.41%)

Close on Nov 17, 2026Market cap $1.55BP/E –Yield –

Earnings

Teladoc Health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$605.10M
-3.4% on a year earlier
EPS, Q3 FY2026
-$0.15
Latest guidance
Lowered
Oct 28, 2026 · 17 items

Quarterly results

Revenue and earnings per share from each of Teladoc Health's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$605.10M-3.4%-$0.15Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026after the close$606.90M-4.0%-$0.21Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026after the close$613.80M-2.5%–Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$642.30M+0.3%-$0.14Release
Q3 FY2025ended Sep 30, 2025Oct 23, 2025after the close$626.40M-2.2%–Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025after the close$631.90M-1.6%-$0.19Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025after the close$629.40M–-$0.53Release
Q4 FY2024ended Dec 31, 2024Feb 26, 2025after the close$640.50M-3.0%-$0.28Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024after the close$640.50M-3.0%–Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024after the close$642.40M-1.5%-$4.92Release
Q1 FY2024ended Mar 31, 2024Apr 5, 2024after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Teladoc Health's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueGAAPQ4 FY2026$569.00M – $615.00M–NewOct 28, 2026
Adjusted EBITDAnon-GAAPQ4 FY2026$74.00M – $100.00M–NewOct 28, 2026
Net loss per shareGAAPQ4 FY2026-$0.23 – -$0.03–NewOct 28, 2026
BetterHelp Adjusted EBITDA marginnon-GAAPQ4 FY20269.2% – 15.1%–LoweredOct 28, 2026
BetterHelp Revenue growth percentage (year-over-year)Q4 FY2026-31.5% – -18.5%–LoweredOct 28, 2026
Integrated Care Adjusted EBITDA marginnon-GAAPQ4 FY202614.5% – 16.8%–NewOct 28, 2026
Integrated Care Revenue growth percentage (year-over-year)Q4 FY20260% – +3.8%–NewOct 28, 2026
U.S. Integrated Care Members (2)Q4 FY202699.5 – 100.5–NewOct 28, 2026
Integrated Care Revenue growth percentage (year-over-year)FY2026+0.8% – +2.4%+0.4% – +3.9%RaisedJul 29, 2026
RevenueGAAPFY2026$2.40B – $2.44B–NewOct 28, 2026
RevenueFY2026$2.36B – $2.45B$2.47B – $2.59BLoweredJul 29, 2026
Integrated Care Adjusted EBITDA marginnon-GAAPFY202615.1% – 16.1%–NewFeb 25, 2026
Adjusted EBITDAnon-GAAPFY2026$277.00M – $303.00M–NewOct 28, 2026
Adjusted EBITDAnon-GAAPFY2026$271.00M – $303.00M$266.00M – $308.00MNarrowedJul 29, 2026
Net loss per shareGAAPFY2026-$0.95 – -$0.75–NewOct 28, 2026
Net loss per shareGAAPFY2026-$1.00 – -$0.75-$1.10 – -$0.70NarrowedJul 29, 2026
Free Cash Flownon-GAAPFY2026$135.00M – $165.00M–NewOct 28, 2026
Free Cash Flownon-GAAPFY2026$130.00M – $170.00M$130.00M – $170.00MReaffirmedJul 29, 2026
BetterHelp Adjusted EBITDA marginnon-GAAPFY20262.7% – 4.3%–LoweredOct 28, 2026
BetterHelp Adjusted EBITDA marginnon-GAAPFY20263% – 4.6%–LoweredJul 29, 2026
BetterHelp Revenue growth percentage (year-over-year)FY2026-16.1% – -12.9%–LoweredOct 28, 2026
Integrated Care Adjusted EBITDA marginnon-GAAPFY202616% – 16.6%–NewOct 28, 2026
Integrated Care Adjusted EBITDA marginnon-GAAPFY202615.6% – 16.4%–NewJul 29, 2026
Integrated Care Revenue growth percentage (year-over-year)FY2026+1.1% – +2.1%–NewOct 28, 2026
U.S. Integrated Care MembersFY202698.5 – 100.597 – 100RaisedJul 29, 2026
U.S. Integrated Care Members (2)FY202699.5 – 100.5–NewOct 28, 2026

Guidance vs results

The last range Teladoc Health gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q3 FY2026EPS (GAAP)-$0.30 – -$0.20-$0.15Above range
Q3 FY2026Revenue$569.00M – $609.00M$605.10MWithin range
Q3 FY2026Revenue growth0% – +3%-3.4%Below range
Q1 FY2026Revenue$598.00M – $620.00M$613.80MWithin range
Q1 FY2026Revenue growth-1.2% – +2%-2.48%Below range
Q3 FY2025Revenue$614.00M – $636.00M$626.40MWithin range
Q2 FY2025EPS (GAAP)-$0.40 – -$0.20-$0.19Above range
Q2 FY2025Revenue$614.00M – $633.00M$631.90MWithin range
Q1 FY2025EPS (GAAP)-$0.40 – -$0.15-$0.53Below range
Q1 FY2025Revenue$608.00M – $629.00M$629.40MAbove range
Q3 FY2024Revenue growth-1% – +2%-2.98%Below range
Q4 FY2023EPS (GAAP)-$0.33 – -$0.23-$0.17Above range

Guidance history

Every forecast Teladoc Health put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted EBITDAQ4 FY2026$74.00M – $100.00MNew
Oct 28, 2026Adjusted EBITDAFY2026$277.00M – $303.00MNew
Oct 28, 2026Net loss per shareQ4 FY2026-$0.23 – -$0.03New
Oct 28, 2026Net loss per shareFY2026-$0.95 – -$0.75New
Oct 28, 2026Free Cash FlowFY2026$135.00M – $165.00MNew
Oct 28, 2026U.S. Integrated Care Members (2)Q4 FY202699.5 – 100.5New
Oct 28, 2026Integrated Care Adjusted EBITDA marginQ4 FY202614.5% – 16.8%New
Oct 28, 2026BetterHelp Adjusted EBITDA marginQ4 FY20269.2% – 15.1%Lowered
Oct 28, 2026Integrated Care Revenue growth percentage (year-over-year)Q4 FY20260% – +3.8%New
Oct 28, 2026BetterHelp Revenue growth percentage (year-over-year)Q4 FY2026-31.5% – -18.5%Lowered
Oct 28, 2026U.S. Integrated Care Members (2)FY202699.5 – 100.5New
Oct 28, 2026Integrated Care Adjusted EBITDA marginFY202616% – 16.6%New
Oct 28, 2026BetterHelp Adjusted EBITDA marginFY20262.7% – 4.3%Lowered
Oct 28, 2026Integrated Care Revenue growth percentage (year-over-year)FY2026+1.1% – +2.1%New
Oct 28, 2026BetterHelp Revenue growth percentage (year-over-year)FY2026-16.1% – -12.9%Lowered
Oct 28, 2026RevenueQ4 FY2026$569.00M – $615.00MNew
Oct 28, 2026RevenueFY2026$2.40B – $2.44BNew
Jul 29, 2026Adjusted EBITDAFY2026$271.00M – $303.00MNarrowed
Jul 29, 2026Adjusted EBITDAQ3 FY2026$62.00M – $74.00MNew
Jul 29, 2026Net loss per shareFY2026-$1.00 – -$0.75Narrowed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Teladoc Health filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Results
  6. Update
  7. Results
  8. Update
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?